Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

References for PMC Articles for PubMed (Select 18938247)

1.

Identification of proteins in human substantia nigra.

Kitsou E, Pan S, Zhang J, Shi M, Zabeti A, Dickson DW, Albin R, Gearing M, Kashima DT, Wang Y, Beyer RP, Zhou Y, Pan C, Caudle WM, Zhang J.

Proteomics Clin Appl. 2008 May;2(5):776-82. doi: 10.1002/prca.200800028.

PMID:
21136874
2.

Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease.

Caudle WM, Pan S, Shi M, Quinn T, Hoekstra J, Beyer RP, Montine TJ, Zhang J.

Proteomics Clin Appl. 2008 Oct;2(10-11):1484-97. doi: 10.1002/prca.200800043. Epub 2008 Sep 10.

3.

Proteomics of human cerebrospinal fluid - the good, the bad, and the ugly.

Zhang J.

Proteomics Clin Appl. 2007 Aug;1(8):805-19. doi: 10.1002/prca.200700081. Epub 2007 Jul 13.

PMID:
21136735
4.

Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS.

Jimenez CR, El Filali Z, Knol JC, Hoekman K, Kruyt FA, Giaccone G, Smit AB, Li KW.

Proteomics Clin Appl. 2007 Jun;1(6):598-604. doi: 10.1002/prca.200600483. Epub 2007 May 11.

PMID:
21136711
5.

Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: Optimization of magnetic bead-based peptide capture and analysis of preanalytical variables.

Jimenez CR, Koel-Simmelink M, Pham TV, van der Voort L, Teunissen CE.

Proteomics Clin Appl. 2007 Nov;1(11):1385-92. doi: 10.1002/prca.200700330. Epub 2007 Oct 16.

PMID:
21136638
6.

Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease.

Hu Y, Hosseini A, Kauwe JS, Gross J, Cairns NJ, Goate AM, Fagan AM, Townsend RR, Holtzman DM.

Proteomics Clin Appl. 2007 Nov;1(11):1373-84. doi: 10.1002/prca.200600999. Epub 2007 Oct 16.

PMID:
21136637
7.

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia.

Clark CM, Pratico D, Shaw LM, Leight S, Xie SX, Gu A, Lee VM, Trojanowski JQ.

Alzheimers Dement. 2006 Oct;2(4):287-93. doi: 10.1016/j.jalz.2006.05.2347. No abstract available.

8.

Glycoprotein enrichment through lectin affinity techniques.

Mechref Y, Madera M, Novotny MV.

Methods Mol Biol. 2008;424:373-96. doi: 10.1007/978-1-60327-064-9_29. Review.

PMID:
18369876
9.

CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.

Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ.

Am J Clin Pathol. 2008 Apr;129(4):526-9. doi: 10.1309/W01Y0B808EMEH12L.

10.

Proteome analysis of human substantia nigra in Parkinson's disease.

Werner CJ, Heyny-von Haussen R, Mall G, Wolf S.

Proteome Sci. 2008 Feb 14;6:8. doi: 10.1186/1477-5956-6-8.

11.

Mortalin: a protein associated with progression of Parkinson disease?

Shi M, Jin J, Wang Y, Beyer RP, Kitsou E, Albin RL, Gearing M, Pan C, Zhang J.

J Neuropathol Exp Neurol. 2008 Feb;67(2):117-24. doi: 10.1097/nen.0b013e318163354a.

PMID:
18219256
12.

Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers.

Aarsland D, Kurz M, Beyer M, Bronnick K, Piepenstock Nore S, Ballard C.

Dement Geriatr Cogn Disord. 2008;25(3):195-205. doi: 10.1159/000113417. Epub 2008 Jan 17. Review.

PMID:
18204253
13.

Label-free comparative analysis of proteomics mixtures using chromatographic alignment of high-resolution muLC-MS data.

Finney GL, Blackler AR, Hoopmann MR, Canterbury JD, Wu CC, MacCoss MJ.

Anal Chem. 2008 Feb 15;80(4):961-71. doi: 10.1021/ac701649e. Epub 2008 Jan 12.

PMID:
18189369
14.

Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform.

Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C, Pan C, Wang Y, Oh JH, Gao J, Zhang J, Montine T, Zhang J.

J Proteome Res. 2008 Feb;7(2):720-30. doi: 10.1021/pr700630x. Epub 2008 Jan 11.

PMID:
18186601
15.

Secretion of DJ-1 into the serum of patients with Parkinson's disease.

Maita C, Tsuji S, Yabe I, Hamada S, Ogata A, Maita H, Iguchi-Ariga SM, Sasaki H, Ariga H.

Neurosci Lett. 2008 Jan 24;431(1):86-9. Epub 2007 Dec 4.

PMID:
18162323
16.

Biomarkers for early detection of Alzheimer pathology.

Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee VM, Trojanowski JQ.

Neurosignals. 2008;16(1):11-8. Epub 2007 Dec 5. Review.

17.

An update on lipidomics: progress and application in biomarker and drug development.

Han X.

Curr Opin Mol Ther. 2007 Dec;9(6):586-91. Review.

PMID:
18041669
18.

Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

Skovronsky DM, Lee VM, Trojanowski JQ.

Annu Rev Pathol. 2006;1:151-70. Review.

PMID:
18039111
19.

Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations.

Kiehntopf M, Siegmund R, Deufel T.

Clin Chem Lab Med. 2007;45(11):1435-49. Review.

PMID:
17970700
20.

Current state and future directions of neurochemical biomarkers for Alzheimer's disease.

de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM.

Clin Chem Lab Med. 2007;45(11):1421-34. Review.

PMID:
17970699
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk